These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. Kantarjian H Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361 [No Abstract] [Full Text] [Related]
4. Two new agents effective in Gleevec-resistant CML. Cancer Biol Ther; 2004 Dec; 3(12):1198-9. PubMed ID: 15864854 [No Abstract] [Full Text] [Related]
5. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML? Breccia M Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419 [No Abstract] [Full Text] [Related]
6. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia]. Liu H; Chen XG Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546 [No Abstract] [Full Text] [Related]
7. [State of the art in the treatment of chronic leukemias]. Ohnishi K Rinsho Ketsueki; 2006 Apr; 47(4):278-86. PubMed ID: 16715962 [No Abstract] [Full Text] [Related]
8. 10 years of progress in chronic myelogenous leukemia. Jabbour E; Mathisen MS; O'Brien S J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803 [No Abstract] [Full Text] [Related]
9. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966 [No Abstract] [Full Text] [Related]
10. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. Schiffer CA N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461 [No Abstract] [Full Text] [Related]
11. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. Kantarjian H; Cortes J J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680 [TBL] [Abstract][Full Text] [Related]